Inflamm Bowel Dis. 2020 May 12;izaa109.doi: 10.1093/ibd/izaa109. Online ahead of print.

Melissa H Rosen ¹, Jordan Axelrad ¹, David Hudesman ¹, David T Rubin ², Shannon Chang ¹

Author information

¹Division of Gastroenterology and Hepatology, NYU Langone Health, New York, NY.

²University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, IL.

Free PMC article

Abstract

First detected in Wuhan, China, the novel 2019 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an enveloped RNA beta-coronavirus responsible for an unprecedented, worldwide pandemic caused by COVID-19. Optimal management of immunosuppression in inflammatory bowel disease (IBD) patients with COVID-19 infection currently is based on expert opinion, given the novelty of the infection and the corresponding lack of high-level evidence in patients with immune-mediated conditions. There are limited data regarding IBD patients with COVID-19 and no data regarding early pregnancy in the era of COVID-19. This article describes a patient with acute severe ulcerative colitis (UC) during her first trimester of pregnancy who also has COVID-19. The case presentation is followed by a review of the literature to date on COVID-19 in regard to inflammatory bowel disease and pregnancy, respectively.